Celerion, a leader in early clinical research, delivers Applied Translational Medicine.
Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines.
Celerion helps drug developers capture and understand early signals of activity and confirmation of drug mechanism in humans through use of relevant biomarker technologies. By applying innovative technology and study designs, the potential risk of positive or equivocal signs of drug toxicity from preclinical studies can often be addressed in early clinical studies. Drug-drug interactions predicted from in vitro testing of human drug metabolizing enzymes and drug transporters are readily assessed in the highly controlled study environment provided by Celerion’s research clinics.
Applying translational medicine in these ways is particularly important in managing investment risk early in clinical drug development.